- Oncothyreon (ONTY) surges 29% after saying that Merck KGa (MKGAF.PK) intends to carry out a Phase III trial of Oncothyreon's tecemotide immunotherapy in patients with advanced non-small cell lung cancer.
- While tecemotide failed to meet the primary goal of a previous trial of improving survival in the overall patient population, the drug did achieve survival times 30.8 months vs 20.6 months for a placebo in a sub-group. (PR)
Merck to take Oncothyreon cancer drug into new Phase III trial
Sep 25 2013, 07:35 ET